Effective Triple-Negative Breast Cancer Targeted Treatment Using iRGD-Modified RBC Membrane-Camouflaged Nanoparticles

Código QR

Effective Triple-Negative Breast Cancer Targeted Treatment Using iRGD-Modified RBC Membrane-Camouflaged Nanoparticles

Jingbin Huang,&ast; Wenjing Lai,&ast; Qing Wang, Qin Tang, Changpeng Hu, Min Zhou, Fengling Wang, Dandan Xie, Qian Zhang, Wuyi Liu, Zhe Zhang, Rong Zhang Department of Pharmacy, The Second Affiliated Hospital of Army Medical University, ChongQing, People’s Republic of China&ast;These aut...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Huang J, Lai W, Wang Q, Tang Q, Hu C, Zhou M, Wang F, Xie D, Zhang Q, Liu W, Zhang Z, Zhang R
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	rbc membrane irgd peptide biological camouflage targeted treatment triple-negative breast cancer. Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/3cf24a51db6440ef8ec99293759590d9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Co-Administration Of iRGD Enhances Tumor-Targeted Delivery And Anti-Tumor Effects Of Paclitaxel-Loaded PLGA Nanoparticles For Colorectal Cancer Treatment
por: Zhong Y, et al.
Publicado: (2019)

Antitumor Activity of Thermosensitive Hydrogels Packaging Gambogic Acid Nanoparticles and Tumor-Penetrating Peptide iRGD Against Gastric Cancer
por: Zhang D, et al.
Publicado: (2020)

iRGD-modified lipid–polymer hybrid nanoparticles loaded with isoliquiritigenin to enhance anti-breast cancer effect and tumor-targeting ability
por: Gao F, et al.
Publicado: (2017)

Engineering of Neutrophil Membrane Camouflaging Nanoparticles Realizes Targeted Drug Delivery for Amplified Antitumor Therapy
por: Wang J, et al.
Publicado: (2021)

RGD-conjugated mesoporous silica-encapsulated gold nanorods enhance the sensitization of triple-negative breast cancer to megavoltage radiation therapy
por: Zhao N, et al.
Publicado: (2016)

Cellular uptake mechanism and comparative evaluation of antineoplastic effects of paclitaxel–cholesterol lipid emulsion on triple-negative and non-triple-negative breast cancer cell lines
por: Ye J, et al.
Publicado: (2016)

Current advances in biomarkers for targeted therapy in triple-negative breast cancer
por: Fleisher B, et al.
Publicado: (2016)

Synovitis in mice with inflammatory arthritis monitored with quantitative analysis of dynamic contrast-enhanced NIR fluorescence imaging using iRGD-targeted liposomes as fluorescence probes
por: Wu H, et al.
Publicado: (2018)

Self-Assembled Dual-Targeted Epirubicin-Hybrid Polydopamine Nanoparticles for Combined Chemo-Photothermal Therapy of Triple-Negative Breast Cancer
por: Li X, et al.
Publicado: (2020)

Anti-EGFR-iRGD recombinant protein modified biomimetic nanoparticles loaded with gambogic acid to enhance targeting and antitumor ability in colorectal cancer treatment
por: Zhang Z, et al.
Publicado: (2018)

Prognostic value of androgen receptor expression in triple negative breast carcinomas: personal experience and comments on a review about “Triple-negative breast cancer: treatment challenges and solutions” by Collignon et al
por: Ieni A, et al.
Publicado: (2016)

Establishment and validation of an individualized macrophage-related gene signature to predict overall survival in patients with triple negative breast cancer
por: Peng Su, et al.
Publicado: (2021)

Encapsulating Halofuginone Hydrobromide in TPGS Polymeric Micelles Enhances Efficacy Against Triple-Negative Breast Cancer Cells
por: Zuo R, et al.
Publicado: (2021)

The Clinical Value of Chemotherapy Combined With Capecitabine in Triple-Negative Breast Cancer—A Meta-Analysis
por: Zilin Zhang, et al.
Publicado: (2021)

Palmatine sensitizes chemoresistant triple negative breast cancer cells via efflux inhibition of multidrug resistant protein 1.
por: Selase Ativui, et al.
Publicado: (2021)

Co-Administration of iRGD with Sorafenib-Loaded Iron-Based Metal-Organic Framework as a Targeted Ferroptosis Agent for Liver Cancer Therapy
por: Liu X, et al.
Publicado: (2021)

IMMUNOHISTOCHEMICAL EXPRESSION OF ANDROGEN RECEPTOR IN TRIPLE NEGATIVE BREAST CARCINOMA AT ARMED FORCES INSTITUTE OF PATHOLOGY, RAWALPINDI
por: Amna Ameer, et al.
Publicado: (2021)

Triple-negative breast cancer: treatment challenges and solutions
por: Collignon J, et al.
Publicado: (2016)

iRGD‐modified exosomes effectively deliver CPT1A siRNA to colon cancer cells, reversing oxaliplatin resistance by regulating fatty acid oxidation
por: Dan Lin, et al.
Publicado: (2021)

Antiangiogenic therapy for breast cancer with triple negative phenotype
por: Inna P. Ganshina, et al.
Publicado: (2021)

Prognostic and clinicopathological values of tissue expression of MFAP5 and ITM2A in triple-negative breast cancer: an immunohistochemical study
por: Abdulwahab Abuderman, et al.
Publicado: (2020)

Trop-2 Therapy in Metastatic Triple-Negative Breast Cancer in Italy: Clinical Opportunity and Regulatory Pitfalls
por: Sara Bravaccini, et al.
Publicado: (2021)

IMMUNOHISTOCHEMICAL EXPRESSION OF ANDROGEN RECEPTOR IN TRIPLE NEGATIVE BREAST CARCINOMA AT ARMED FORCES INSTITUTE OF PATHOLOGY, RAWALPINDI
por: Amna Ameer, et al.
Publicado: (2021)

A Combined Nomogram Model to Predict Disease-free Survival in Triple-Negative Breast Cancer Patients With Neoadjuvant Chemotherapy
por: Bingqing Xia, et al.
Publicado: (2021)

Indocyanine Green-Parthenolide Thermosensitive Liposome Combination Treatment for Triple-Negative Breast Cancer
por: Jin X, et al.
Publicado: (2020)

Molecular-Genetic Portrait of Breast Cancer with Triple Negative Phenotype
por: Marina K. Ibragimova, et al.
Publicado: (2021)

Identifying the Effect of Ursolic Acid Against Triple-Negative Breast Cancer: Coupling Network Pharmacology With Experiments Verification
por: Yubao Zhang, et al.
Publicado: (2021)

Resultados del tratamiento del cáncer de mama, Programa Nacional de Cáncer del Adulto
por: Castillo,César del SM., et al.
Publicado: (2017)

ARNTL2 is a Prognostic Biomarker and Correlates with Immune Cell Infiltration in Triple-Negative Breast Cancer
por: Wang X, et al.
Publicado: (2021)

Role of PTEN, PI3K, and mTOR in Triple-Negative Breast Cancer
por: Mirjana Prvanović, et al.
Publicado: (2021)

Real-World Data from a Refractory Triple-Negative Breast Cancer Cohort Selected Using a Clinical Data Warehouse Approach
por: Hana Kim, et al.
Publicado: (2021)

Inhibition of Vasculogenic Mimicry and Angiogenesis by an Anti-EGFR IgG1-Human Endostatin-P125A Fusion Protein Reduces Triple Negative Breast Cancer Metastases
por: Seung-Uon Shin, et al.
Publicado: (2021)

iRGD Peptide-Mediated Liposomal Nanoparticles with Photoacoustic/Ultrasound Dual-Modality Imaging for Precision Theranostics Against Hepatocellular Carcinoma
por: Li H, et al.
Publicado: (2021)

Improved Anti-Triple Negative Breast Cancer Effects of Docetaxel by RGD-Modified Lipid-Core Micelles
por: Chen R, et al.
Publicado: (2021)

miR-29b-3p promotes progression of MDA-mB-231 triple-negative breast cancer cells through downregulating TRAF3
por: Zhang,Bao, et al.
Publicado: (2019)

Cytochrome 4Z1 Expression is Associated with Unfavorable Survival in Triple-Negative Breast Cancers
por: Al-saraireh YM, et al.
Publicado: (2021)

Repurposing hyperpolarization‐activated cyclic nucleotide‐gated channels as a novel therapy for breast cancer
por: Ka‐Chun Mok, et al.
Publicado: (2021)

Immune Effect of Active Components of Traditional Chinese Medicine on Triple-Negative Breast Cancer
por: Wenjie Zhao, et al.
Publicado: (2021)

Opportunities for metastatic triple negative breast cancer therapy
por: Inna P. Ganshina, et al.
Publicado: (2021)

Non-Coding RNAs Associated With Radioresistance in Triple-Negative Breast Cancer
por: Alberto Aranza-Martínez, et al.
Publicado: (2021)